Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study. Hosono N, Tomiyama Y, Emori N, Isogaya K, et al. Int J Hematol 2025;122:824-834.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hosono N, Tomiyama Y, Emori N, Isogaya K, et al. Safety of liposomal daunorubicin-cytarabine (CPX-351) in secondary AML: Japanese phase 1/2 study and global phase 3 study. Int J Hematol 2025;122:824-834.
PMID: 40815417